cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14430854.v2
title: Fig. 1e

description: Different subtypes of breast cancer was scored based on proportion of MICA/MICB positive cells. (score 0 (no MICA/MICB expression), score 1 (&lt; 10%), score 2 (10% to 50%) score 3 (51 to 80%) and score 4 (&gt;80%) tumor cells expressing MICA/MICB).
DOI: 10.6084/m9.figshare.14431145
title: Fig. 2c

description: C1R cells expressing different alleles of MICA were incubated with PBMCs from healthy donors and 10 µg/ml of MICAB1-Fc-engineered, MICAB1-Fc silent or isotype control Fc-engineered mAb for 24 hours. The data shown are the frequencies of NK cells expressing CD137 among total NK cells, and are representative of three independent experiments
DOI: 10.6084/m9.figshare.14431145.v3
title: Fig. 2c

description: C1R cells expressing different alleles of MICA were incubated with PBMCs from healthy donors and 10 µg/ml of MICAB1-Fc-engineered, MICAB1-Fc silent or isotype control Fc-engineered mAb for 24 hours. The data shown are the frequencies of NK cells expressing CD137 among total NK cells, and are representative of three independent experiments
DOI: 10.6084/m9.figshare.14431145.v2
title: Fig. 2c

description: C1R cells expressing different alleles of MICA were incubated with PBMCs from healthy donors and 10 µg/ml of MICAB1-Fc-engineered, MICAB1-Fc silent or isotype control Fc-engineered mAb for 24 hours. The data shown are the frequencies of NK cells expressing CD137 among total NK cells, and are representative of three independent experiments
DOI: 10.6084/m9.figshare.14428346
title: Fig. 2d-MFI

description: MICA expression on A549 and Raji MICA001 vs EGFR and CD20 expression
DOI: 10.6084/m9.figshare.14428340
title: Fig. 2d-Lysis

description: PBMCs from healthy donors were incubated with <sup>51</sup>chromium-loaded A549 cells naturally expressing MICA *001:12/*004 and MICB *002/*007 or Raji-MICA*001 in the presence of a range of doses of MICAB1 Fc-engineered or isotype control, cetuximab or rituximab. Upper panels: MFI of mAb binding at the cell surface revealed with a secondary Ab. Lower panels: After four hours, <sup>51</sup>chromium levels were determined in the supernatants. The data shown are representative of three independent experiments.
DOI: 10.6084/m9.figshare.14428340.v4
title: Fig. 2d-Lysis

description: PBMCs from healthy donors were incubated with <sup>51</sup>chromium-loaded A549 cells naturally expressing MICA *001:12/*004 and MICB *002/*007 or Raji-MICA*001 in the presence of a range of doses of MICAB1 Fc-engineered or isotype control, cetuximab or rituximab. Upper panels: MFI of mAb binding at the cell surface revealed with a secondary Ab. Lower panels: After four hours, <sup>51</sup>chromium levels were determined in the supernatants. The data shown are representative of three independent experiments.
DOI: 10.6084/m9.figshare.14428340.v3
title: Fig. 2d-Lysis

description: PBMCs from healthy donors were incubated with <sup>51</sup>chromium-loaded A549 cells naturally expressing MICA *001:12/*004 and MICB *002/*007 or Raji-MICA*001 in the presence of a range of doses of MICAB1 Fc-engineered or isotype control, cetuximab or rituximab. Upper panels: MFI of mAb binding at the cell surface revealed with a secondary Ab. Lower panels: After four hours, <sup>51</sup>chromium levels were determined in the supernatants. The data shown are representative of three independent experiments.
DOI: 10.6084/m9.figshare.14428673
title: Fig. 2e

description: C1R cells expressing MICA*001 or MICA*008 were loaded with PKH67 and added to macrophages in the presence of a range of doses of MICAB1 Fc-engineered or isotype control mAb. The cells were incubated for two hours at 37°C. Macrophage intracellular fluorescence intensity is shown (in relative units) as a function of antibody concentration.Data of one representative donor are shown.
DOI: 10.6084/m9.figshare.14428673.v2
title: Fig. 2e

description: C1R cells expressing MICA*001 or MICA*008 were loaded with PKH67 and added to macrophages in the presence of a range of doses of MICAB1 Fc-engineered or isotype control mAb. The cells were incubated for two hours at 37°C. Macrophage intracellular fluorescence intensity is shown (in relative units) as a function of antibody concentration.Data of one representative donor are shown.
DOI: 10.6084/m9.figshare.14431148
title: Fig. 3a

description: Raji B-cell lymphoma cells expressing the MICA*001 allele were injected iv into NOD-SCID immunodeficient mice simultaneously treated once with a range of doses of MICAB1 (0.05, 0.5, 2.5 or 5 mg/Kg, <i>n</i>=8 to 18, pool of 2 independent experiments) or isotype control mAb (2.5 or 5 mg/kg; <i>n</i>=17). Kaplan–Meier curves of mouse survival are shown. Log-rank Mantel–Cox test: **<i>p</i>=0.0024 100 µg (<i>n</i>=8), **<i>p</i>=0.0081 50 µg (<i>n</i>=10), *<i>p</i>=0.0303 10 µg (<i>n</i>=18).
DOI: 10.6084/m9.figshare.14431148.v2
title: Fig. 3a

description: Raji B-cell lymphoma cells expressing the MICA*001 allele were injected iv into NOD-SCID immunodeficient mice simultaneously treated once with a range of doses of MICAB1 (0.05, 0.5, 2.5 or 5 mg/Kg, <i>n</i>=8 to 18, pool of 2 independent experiments) or isotype control mAb (2.5 or 5 mg/kg; <i>n</i>=17). Kaplan–Meier curves of mouse survival are shown. Log-rank Mantel–Cox test: **<i>p</i>=0.0024 100 µg (<i>n</i>=8), **<i>p</i>=0.0081 50 µg (<i>n</i>=10), *<i>p</i>=0.0303 10 µg (<i>n</i>=18).
DOI: 10.6084/m9.figshare.14431160
title: Fig. 3b

description: Raji B-cell lymphoma cells expressing the MICA*001 or MICA*008 allele with low and medium level were injected i.p. into NOD-SCID immunodeficient mice simultaneously treated once with 0.5 mg/kg of body weight of MICAB1-Fc-engineered mAb or BAMO3 mAb or isotype control mAb. Tumor cell counts in peritoneal cavity lavage 24 hours later are shown. <i>n</i>=8 per group. Kruskal-Wallis test.
DOI: 10.6084/m9.figshare.14431160.v2
title: Fig. 3b

description: Raji B-cell lymphoma cells expressing the MICA*001 or MICA*008 allele with low and medium level were injected i.p. into NOD-SCID immunodeficient mice simultaneously treated once with 0.5 mg/kg of body weight of MICAB1-Fc-engineered mAb or BAMO3 mAb or isotype control mAb. Tumor cell counts in peritoneal cavity lavage 24 hours later are shown. <i>n</i>=8 per group. Kruskal-Wallis test.
DOI: 10.6084/m9.figshare.14431166
title: Fig. 3c

description: B16-F10 MICA*001 were engrafted s.c. in MICAgen mice. Five days later, mice bearing tumors were randomized into two groups (<i>n</i>=10/group) and treated weekly for three weeks with 10 mg/kg of either MICAB1-mIgG2a or isotype control mAb. Tumor volumes per mouse over time are shown
DOI: 10.6084/m9.figshare.14431166.v3
title: Fig. 3c

description: B16-F10 MICA*001 were engrafted s.c. in MICAgen mice. Five days later, mice bearing tumors were randomized into two groups (<i>n</i>=10/group) and treated weekly for three weeks with 10 mg/kg of either MICAB1-mIgG2a or isotype control mAb. Tumor volumes per mouse over time are shown
DOI: 10.6084/m9.figshare.14431166.v2
title: Fig. 3c

description: B16-F10 MICA*001 were engrafted s.c. in MICAgen mice. Five days later, mice bearing tumors were randomized into two groups (<i>n</i>=10/group) and treated weekly for three weeks with 10 mg/kg of either MICAB1-mIgG2a or isotype control mAb. Tumor volumes per mouse over time are shown
DOI: 10.6084/m9.figshare.14431181
title: Fig. 3d

description: Doubling time of tumor volumes B16F10 MICA*001 from (3c) are shown
DOI: 10.6084/m9.figshare.14431181.v2
title: Fig. 3d

description: Doubling time of tumor volumes B16F10 MICA*001 from (3c) are shown
DOI: 10.6084/m9.figshare.14431385
title: Fig. 4d

description: HER2 HBCx-5 fragment were engrafted into SHO mice. 35 days later, tumor-bearing mice were treated once weekly for eight consecutive weeks, with 0.05 mg/kg MICAB1 PBD1G-ADCs or IC-PDB1G. Tumor growth was followed over time (<i>n</i>=10 per group).
DOI: 10.6084/m9.figshare.14431385.v2
title: Fig. 4d

description: HER2 HBCx-5 fragment were engrafted into SHO mice. 35 days later, tumor-bearing mice were treated once weekly for eight consecutive weeks, with 0.05 mg/kg MICAB1 PBD1G-ADCs or IC-PDB1G. Tumor growth was followed over time (<i>n</i>=10 per group).
DOI: 10.6084/m9.figshare.14431400
title: Fig. 4e

description: B16F10 cells expressing MICA*001 were engrafted, s.c., into C57BL/6 mice. 4 days later, when tumors reach 150 mm<sup>3</sup>, mice were randomized to six groups and treated once weekly for three consecutive weeks with 0.1 mg/kg, 0.25 mg/kg or 0.5 mg/kg MICAB1 PBD1G-ADCs or IC-PBD1G.<b> </b>Kaplan–Meier curves showing mouse survival (<i>n</i>=12 per group). Mantel-Cox test, **** p&lt;0.0001 (0.5 mg/kg and 0.25 mg/kg) and ***p&lt;0.001 (0.1mg/kg). Right panels: Cured mice (<i>n</i>=9) and naïve mice (<i>n</i>=10) were re-challenged s.c. with B16F10 expressing MICA*001 on one flank. Some cured mice (<i>n</i>=4) were not re-challenged and monitored for eventual tumor regrowth
DOI: 10.6084/m9.figshare.14431400.v3
title: Fig. 4e

description: B16F10 cells expressing MICA*001 were engrafted, s.c., into C57BL/6 mice. 4 days later, when tumors reach 150 mm<sup>3</sup>, mice were randomized to six groups and treated once weekly for three consecutive weeks with 0.1 mg/kg, 0.25 mg/kg or 0.5 mg/kg MICAB1 PBD1G-ADCs or IC-PBD1G.<b> </b>Kaplan–Meier curves showing mouse survival (<i>n</i>=12 per group). Mantel-Cox test, **** p&lt;0.0001 (0.5 mg/kg and 0.25 mg/kg) and ***p&lt;0.001 (0.1mg/kg). Right panels: Cured mice (<i>n</i>=9) and naïve mice (<i>n</i>=10) were re-challenged s.c. with B16F10 expressing MICA*001 on one flank. Some cured mice (<i>n</i>=4) were not re-challenged and monitored for eventual tumor regrowth
DOI: 10.6084/m9.figshare.14431400.v2
title: Fig. 4e

description: B16F10 cells expressing MICA*001 were engrafted, s.c., into C57BL/6 mice. 4 days later, when tumors reach 150 mm<sup>3</sup>, mice were randomized to six groups and treated once weekly for three consecutive weeks with 0.1 mg/kg, 0.25 mg/kg or 0.5 mg/kg MICAB1 PBD1G-ADCs or IC-PBD1G.<b> </b>Kaplan–Meier curves showing mouse survival (<i>n</i>=12 per group). Mantel-Cox test, **** p&lt;0.0001 (0.5 mg/kg and 0.25 mg/kg) and ***p&lt;0.001 (0.1mg/kg). Right panels: Cured mice (<i>n</i>=9) and naïve mice (<i>n</i>=10) were re-challenged s.c. with B16F10 expressing MICA*001 on one flank. Some cured mice (<i>n</i>=4) were not re-challenged and monitored for eventual tumor regrowth
DOI: 10.6084/m9.figshare.14428682
title: Fig. 5a

description: Lung adenocarcinoma H1703 cells were engrafted s.c. in nude mice. 9 days later, tumor-bearing mice were randomized to three groups and treated once with 0.3 mg/kg MICAB1 PDB2G-ADCs, IC-PBD2G or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=9 per group).
DOI: 10.6084/m9.figshare.14428682.v3
title: Fig. 5a

description: Lung adenocarcinoma H1703 cells were engrafted s.c. in nude mice. 9 days later, tumor-bearing mice were randomized to three groups and treated once with 0.3 mg/kg MICAB1 PDB2G-ADCs, IC-PBD2G or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=9 per group).
DOI: 10.6084/m9.figshare.14430812
title: Fig. 5b

description: HCT-116 cells were engrafted s.c. in nude mice. 5 to 6 days later, tumor-bearing mice were randomized to six groups and treated once with 0.5, 1 or 2 mg/kg MICAB1 PDB2G-ADCs, IC-PBD2G or vehicle. Tumor growth was followed over time (<i>n</i>=8-9 per group). Representative data from two independent experiments are shown
DOI: 10.6084/m9.figshare.14430812.v3
title: Fig. 5b

description: HCT-116 cells were engrafted s.c. in nude mice. 5 to 6 days later, tumor-bearing mice were randomized to six groups and treated once with 0.5, 1 or 2 mg/kg MICAB1 PDB2G-ADCs, IC-PBD2G or vehicle. Tumor growth was followed over time (<i>n</i>=8-9 per group). Representative data from two independent experiments are shown
DOI: 10.6084/m9.figshare.14430812.v2
title: Fig. 5b

description: HCT-116 cells were engrafted s.c. in nude mice. 5 to 6 days later, tumor-bearing mice were randomized to six groups and treated once with 0.5, 1 or 2 mg/kg MICAB1 PDB2G-ADCs, IC-PBD2G or vehicle. Tumor growth was followed over time (<i>n</i>=8-9 per group). Representative data from two independent experiments are shown
DOI: 10.6084/m9.figshare.14430821
title: Fig. 5c

description: HER2 HBCx-5 or luminal HBCx-34 PDX were engrafted into nude mice. 35 to 38 days later, tumor-bearing mice were treated once with 0.5 mg/kg MICAB1 PBD2G-ADCs or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=10 per group).
DOI: 10.6084/m9.figshare.14430821.v3
title: Fig. 5c

description: HER2 HBCx-5 or luminal HBCx-34 PDX were engrafted into nude mice. 35 to 38 days later, tumor-bearing mice were treated once with 0.5 mg/kg MICAB1 PBD2G-ADCs or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=10 per group).
DOI: 10.6084/m9.figshare.14430821.v2
title: Fig. 5c

description: HER2 HBCx-5 or luminal HBCx-34 PDX were engrafted into nude mice. 35 to 38 days later, tumor-bearing mice were treated once with 0.5 mg/kg MICAB1 PBD2G-ADCs or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=10 per group).
DOI: 10.6084/m9.figshare.14432477
title: Fig. 5e

description: MCA tumors were dissociated and stained with MICAB1 or IC-APC mAb. MICA cell surface expression was determined by flow cytometry.TG21 = MICAGEN mice 19E9 = MICAB1<br>
DOI: 10.6084/m9.figshare.14432477.v3
title: Fig. 5e

description: MCA tumors were dissociated and stained with MICAB1 or IC-APC mAb. MICA cell surface expression was determined by flow cytometry.TG21 = MICAGEN mice 19E9 = MICAB1<br>
DOI: 10.6084/m9.figshare.14432477.v2
title: Fig. 5e

description: MCA tumors were dissociated and stained with MICAB1 or IC-APC mAb. MICA cell surface expression was determined by flow cytometry.TG21 = MICAGEN mice 19E9 = MICAB1<br>
DOI: 10.6084/m9.figshare.14430833
title: Fig. 5f

description: MICAgen mice were treated sc with 100 µg MCA. Around 100 days later, mice bearing fibrosarcomas were randomized to five groups and treated once with vehicle or 0.5 or 2 mg/kg MICAB1 PDB2G-ADCs or IC-PDB2G or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=15 per group)
DOI: 10.6084/m9.figshare.14430833.v2
title: Fig. 5f

description: MICAgen mice were treated sc with 100 µg MCA. Around 100 days later, mice bearing fibrosarcomas were randomized to five groups and treated once with vehicle or 0.5 or 2 mg/kg MICAB1 PDB2G-ADCs or IC-PDB2G or vehicle. Tumor volumes per mouse over time are shown (<i>n</i>=15 per group)
DOI: 10.6084/m9.figshare.14432729
title: Fig. 5g

description: MICAgen mice were injected s.c. with MCA. Around 100 days later, mice bearing fibrosarcomas were randomized in 4 groups. Two groups were treated once with 2 mg/kg of MICAB1 PDB2G-ADCs or IC-PDB2Gand two groups were treated once a week for three weeks with 10 mg/kg of mIgG2a-MICAB1 or mIgG2a-IC.
DOI: 10.5519/qd.aj1g2d0m
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (91 records)
DOI: 10.6084/m9.figshare.7731464
title: Raw data and scripts from "A Topological Sorting Approach to Identify Congested Flowgates within Power Grids"

description: This paper proposes a new technique to identify sets of branches that form heavily loaded and potentially vulnerable flowgates within power grids. To this end, a directed acyclic graph is used to model the instantaneous state of power grids. One of the advantages of directed acyclic graphs is they allow the identification of where power flows are coherent e.g where power flows in a uniform direction along a set of branches that partition the network into two islands. This paper uses topological sorts to identify many sets of branches having this property. Definitions are provided for two new concepts, termed coherent cut-sets and coherent crack-sets, which are particular sets of branches extracted from a specific topological sort. Notably, there are numerous possible topological sorts for a directed acyclic graph and calculating distinctive topological sorts is challenging. In this paper a novel optimization algorithm is proposed to find multiple, diverse topological sorts each of which implies many cut-sets. The effectiveness of the proposed methods for enhancing grid observability and situational awareness is demonstrated using two standard test networks.<br>
DOI: 10.6084/m9.figshare.7731464.v1
title: Raw data and scripts from "A Topological Sorting Approach to Identify Congested Flowgates within Power Grids"

description: This paper proposes a new technique to identify sets of branches that form heavily loaded and potentially vulnerable flowgates within power grids. To this end, a directed acyclic graph is used to model the instantaneous state of power grids. One of the advantages of directed acyclic graphs is they allow the identification of where power flows are coherent e.g where power flows in a uniform direction along a set of branches that partition the network into two islands. This paper uses topological sorts to identify many sets of branches having this property. Definitions are provided for two new concepts, termed coherent cut-sets and coherent crack-sets, which are particular sets of branches extracted from a specific topological sort. Notably, there are numerous possible topological sorts for a directed acyclic graph and calculating distinctive topological sorts is challenging. In this paper a novel optimization algorithm is proposed to find multiple, diverse topological sorts each of which implies many cut-sets. The effectiveness of the proposed methods for enhancing grid observability and situational awareness is demonstrated using two standard test networks.<br>
DOI: 10.6084/m9.figshare.15138177
title: Effect of social support through social media and online class participation on the psychological resilience of prospective special educational needs teachers during the COVID-19 lockdown

description: <b>Effect of social support through social media and online class participation on the psychological resilience of prospective special educational needs teachers during the COVID-19 lockdown</b> @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:11.0pt; mso-ansi-font-size:11.0pt; mso-bidi-font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-fareast-language:EN-US;}.MsoPapDefault {mso-style-type:export-only; margin-bottom:8.0pt; line-height:107%;}div.WordSection1 {page:WordSection1;}
DOI: 10.6084/m9.figshare.15138177.v1
title: Effect of social support through social media and online class participation on the psychological resilience of prospective special educational needs teachers during the COVID-19 lockdown

description: <b>Effect of social support through social media and online class participation on the psychological resilience of prospective special educational needs teachers during the COVID-19 lockdown</b> @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:11.0pt; mso-ansi-font-size:11.0pt; mso-bidi-font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-fareast-language:EN-US;}.MsoPapDefault {mso-style-type:export-only; margin-bottom:8.0pt; line-height:107%;}div.WordSection1 {page:WordSection1;}
DOI: 10.25345/c53r82
title: MassIVE MSV000087959 - Physiological and proteomic analyses of different ecotypes of Phragmits communis in adaption to natural drought and salinity
title: Drought and salinity are two major abiotic stresses constraining crop yield worldwide. Both of them trigger cellular dehydration and cause osmotic stress which leads to cytosolic and vacuolar volume reduction. However, whether plants share a similar tolerance mechanism in response to these two stresses under natural conditions has seldom been comparatively reported.There are three different ecotypes of reed within a 5 km2 region in the Badanjilin desert of Northwest China. Taking the typical swamp reed (SR) as a control, we performed a comparative study on the adaption mechanisms of the two terrestrial ecotypes: dune reed (DR) and heavy salt meadow reed (HSMR) by physiological and proteomic approaches coupled with bioinformatic analysis.The results showed that HSMR and DR have evolved C4-like photosynthetic and anatomical characteristics, such as the increased bundle sheath cells(BSCs) and chloroplasts in BSCs, higher density of veins, and lower density and aperture of stomata. In addition, the thylakoid membrane fluidity also acts an important role in their higher drought and salinity tolerance capability.The proteomic results further demonstrated that HSMR and DR facilitated the regulation of proteins associated with photosynthesis and energy metabolism, lipid metabolism, transcription and translation, and stress responses to well adapt to the drought and salinity conditions.Overall, our results demonstrated that HSMR and DR shaped a similar adaption strategy from the structural and physiological levels to the molecular scale to ensure functionality in the harsh environment.
DOI: 10.5281/zenodo.5172809
title: MultiDCP dataset

description: MultiDCP dataset
DOI: 10.5281/zenodo.5172808
title: MultiDCP dataset

description: MultiDCP dataset
DOI: 10.5517/ccdc.csd.cc27rv73
title: CCDC 2078495: Experimental Crystal Structure Determination

description: Related Article: Yuliya A. Bryleva, Alexander V. Artem’ev, Ludmila A. Glinskaya, Mariana I. Rakhmanova, Denis G. Samsonenko, Vladislav Yu. Komarov, Maxim I. Rogovoy, Maria P. Davydova|2021|New J.Chem.|45|13869|doi:10.1039/D1NJ02441H
DOI: 10.5517/ccdc.csd.cc20j861
title: CCDC 1862672: Experimental Crystal Structure Determination

description: Related Article: Chen Yang, Yu-Heng Wei, Shuang Xu, Hao-Yu Zhang, Yue-Qi Yang, Bo Zhang, Ming Fang|2021|New J.Chem.|45|14103|doi:10.1039/D1NJ01833G
DOI: 10.5517/ccdc.csd.cc20j872
title: CCDC 1862673: Experimental Crystal Structure Determination

description: Related Article: Chen Yang, Yu-Heng Wei, Shuang Xu, Hao-Yu Zhang, Yue-Qi Yang, Bo Zhang, Ming Fang|2021|New J.Chem.|45|14103|doi:10.1039/D1NJ01833G
DOI: 10.5517/ccdc.csd.cc26m512
title: CCDC 2044203: Experimental Crystal Structure Determination

description: Related Article: Suprava Bhunia, Basudeb Dutta, Kunal Pal, Angeera Chandra, Kuladip Jana, Chittaranjan Sinha|2021|New J.Chem.|45|13941|doi:10.1039/D1NJ00917F
DOI: 10.5517/ccdc.csd.cc26m534
title: CCDC 2044205: Experimental Crystal Structure Determination

description: Related Article: Suprava Bhunia, Basudeb Dutta, Kunal Pal, Angeera Chandra, Kuladip Jana, Chittaranjan Sinha|2021|New J.Chem.|45|13941|doi:10.1039/D1NJ00917F
DOI: 10.5517/ccdc.csd.cc27j88b
title: CCDC 2071211: Experimental Crystal Structure Determination

description: Related Article: Tien-Wen Tseng, Tzuoo-Tsair Luo, Kuo-Yang Tseng, Yu-Xian Hong, Guang-Cheng Huang|2021|CrystEngComm|23|5293|doi:10.1039/D1CE00780G